{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:13:34Z","timestamp":1787015614241,"version":"build-2736575974"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["agsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence and prevalence of dementia, and thus dementia\u2010related behavioral and psychological symptoms, are increasing significantly. Currently, there are limited safe and efficacious options for treating these symptoms. Dexmedetomidine has been used for agitation related to delirium and showed significant benefit in prior studies. This raises the question whether dexmedetomidine could also provide a safe and effective treatment for BPSD, including agitation related to dementia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our team searched PubMed, Cochrane Database, and Ovid with the terms dexmedetomidine and dementia. Only studies published in English language journals, or with official English language translations, and human studies were included. All reports of dexmedetomidine for dementia were included regardless of study type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No completed studies on dexmedetomidine for agitation in dementia were identified. The TRANQUILITY study is in progress, although results are yet to be published.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dexmedetomidine has shown benefit for hospital delirium and for agitation in schizophrenia and bipolar disorder. However, there are no completed studies published on dexmedetomidine for agitation in dementia. Controlled studies with larger sample sizes are needed to assess the efficacy, safety, and the best route of administration for this drug in managing BPSD including agitation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgs.19196","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T03:29:03Z","timestamp":1726716543000},"page":"552-557","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dexmedetomidine for agitation in dementia: Current data and future direction"],"prefix":"10.1111","volume":"73","author":[{"given":"Kayla S.","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Psychiatry University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Golden","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Brigham and Women's Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh R.","family":"Tampi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Creighton University  Omaha Nebraska USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S163842"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2012.00073"},{"key":"e_1_2_11_4_1","volume-title":"StatPearls","author":"Cloak N","year":"2024"},{"key":"e_1_2_11_5_1","unstructured":"FDA approves first drug to treat agitation symptoms associated with dementia due to alzheimer's disease.FDA News Release 2023. US Food and Drug Administration (online). Accessed August 5 2024.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010drug\u2010treat\u2010agitation\u2010symptoms\u2010associated\u2010dementia\u2010due\u2010alzheimers\u2010disease"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.3810"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12335"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061240"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2017.10.010"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008191.pub2"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035185"},{"key":"e_1_2_11_12_1","unstructured":"Precedex (dexmedetomidine hydrochloride).Drug Approval Package 1999. US Food and Drug Administration (online). Accessed August 5 2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/21-038_Precedex.cfm"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2023.21.2.215"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910\u2010018\u20100873\u2010z"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/aas.14208"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5406"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231171179"},{"key":"e_1_2_11_18_1","unstructured":"Covidence systematic review software. Veritas Health Innovation Melbourne Australia (online). Accessed August 1 2024.www.covidence.org"},{"key":"e_1_2_11_19_1","unstructured":"Sub\u2010lingual dexmedetomidine in agitation associated with dementia (TRANQUILITY). ClinicalTrials.gov identifier: NCT04251910. Updated Sept 21 2023. Accessed August 5 2024.https:\/\/clinicaltrials.gov\/study\/NCT04251910#study-overview"},{"key":"e_1_2_11_20_1","unstructured":"Bioxcel therapeutics announces BXCL501 met the primary and all secondary endpoints in the TRANQUILITY phase 1b\/2 study for the acute treatment of agitation in dementia including alzheimer's disease. Press Release 2021. Bioxcel therapeutics (online). Accessed August 5 2024.https:\/\/bioxceltherapeutics.gcs-web.com\/node\/6281\/pdf"},{"key":"e_1_2_11_21_1","unstructured":"Bioxcel therapeutics receives FDA breakthrough therapy designation for BXCL501 for the acute treatment of agitation associated with dementia. Press Release 2021. Bioxcel therapeutics (online). Accessed August 5 2024.https:\/\/ir.bioxceltherapeutics.com\/node\/6231\/pdf"},{"key":"e_1_2_11_22_1","unstructured":"Dexmedetomidine in the treatment of agitation associated with dementia (TRANQUILITY II). ClinicalTrials.gov identifier: NCT05271552. Updated Dec 11 2023. Accessed August 5 2024.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05271552"},{"key":"e_1_2_11_23_1","unstructured":"Bioxcel therapeutics announces positive topline results from TRANQUILITY II phase 3 trial of BXCL501 for acute treatment of alzheimer's disease\u2010related agitation. Press Release 2023. Bioxcel therapeutics (online). Accessed August 5 2024.https:\/\/ir.bioxceltherapeutics.com\/node\/11206\/pdf"},{"key":"e_1_2_11_24_1","unstructured":"Dexmedetomidine in the treatment of agitation associated with dementia (TRANQUILITY III). ClinicalTrials.gov identifier: NCT05665088. Updated Dec 8 2023. Accessed Aug 5 2024.https:\/\/ichgcp.net\/clinical\u2010trials\u2010registry\/NCT05665088"},{"key":"e_1_2_11_25_1","unstructured":"Bioxcel therapeutics aligns with FDA recommendation for phase 3 trial for TRANQUILITY program provides update on strategic financing and reports third quarter 2023 financial results. Press Release 2023. Bioxcel therapeutics (online). Accessed August 5 2024.https:\/\/ir.bioxceltherapeutics.com\/node\/11516\/pdf"},{"key":"e_1_2_11_26_1","unstructured":"An efficacy and safety study of BXCL501 for the treatment of agitation with dementia. ClinicalTrials.gov identifier: NCT05276830. Updated Aug 25 2023. Accessed August 5 2024.https:\/\/clinicaltrials.gov\/study\/NCT05276830#conta%20cts-and-locations"},{"key":"e_1_2_11_27_1","unstructured":"Dexmedetomidine transdermal systems (DMTS) treatment for agitation associated with dementia of the alzheimer's type. ClinicalTrials.gov identifier: NCT06052254. Updated Sept 25 2023. Accessed August 5 2024.https:\/\/clinicaltrials.gov\/study\/NCT06052254"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551\u20106776\u201027.7.587"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2017.1505"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.19196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:12:36Z","timestamp":1762193556000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.19196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/jgs.19196"],"URL":"https:\/\/doi.org\/10.1111\/jgs.19196","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"2024-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}